Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation‐positive metastatic melanoma, including recognition and management of rare presentations

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|173|4|1024-1031

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.173, Iss.4, 2015-10, pp. : 1024-1031

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 241-245

Karger

Access to resources Recommend Favorite

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 955-961

John Wiley & Sons Inc

Access to resources Recommend Favorite

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-05 ,pp. : 343-348

Karger

Access to resources Recommend Favorite

Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 3, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients

By  

JOURNAL OF ORAL PATHOLOGY & MEDICINE, Vol. 47, Iss. 1, 2018-01 ,pp. : 86-90

John Wiley & Sons Inc

Access to resources Recommend Favorite